Home     |    Contact ASA     |     Join ASA!    |     Members Only     |    Retail Store   |    Advertising Information
 
ASA NEWSLETTER
 
 
April 2002
Volume 66
Number 4
 

WHAT'S NEW
Therapy of PONV: An Overview

Ashish C. Sinha, M.D., Ph.D.


Patients preparing for surgery frequently express three fears: not waking up after surgery, waking up during surgery and throwing up after surgery. As anesthesiologists we can reassure them about the first, be vigilant against the second and work toward alleviation of the third. The overall incidence of postoperative nausea and vomiting (PONV) is estimated at between one-in-four to one-in-three patients, although this varies considerably from practice to practice, depending upon factors such as types of case (e.g., pediatric or endoscopic), routine prophylactic use of antiemetics and, frequently, time to follow-up. Overall, the PONV odds may vary from three-out-of-five to one-in-20. In our institution, with no obstetric or trauma cases and very few pediatric cases, our incidence of PONV is around 5 percent. As a group, we also are very aggressive about treating PONV preoperatively, intraoperatively and postoperatively.

The etiology and consequences of PONV are complex as well as multifactorial, involving patient, medical problems, surgery and anesthetic technique. The treatment of PONV has at different times involved the use of anticholinergics, phenothiazines, antihistamines, butyrophenones and benzamides. Newer pharmacotherapy of PONV involves serotonin receptor antagonists, steroids and, just over the horizon maybe, NK-1 receptor antagonists.

Traditionally, patient factors that have been associated with increased incidence of PONV have included female sex, young age, obesity, history of motion sickness, history of gastroesophageal dysfunction, smoking, anxiety and even difficult airway. Site of surgery involving the head and neck, oropharynx, ears and eyes as well as intra-abdominal procedures is similarly associated with increased PONV. Anesthetic techniques also affect incidence, being increased by general anesthetic (versus regional and local). With general anesthesia, narcotics and nitrous oxide are more to blame than propofol. Similarly, aggressive bag-mask ventilation or nonuse of an orogastric tube can negatively impact incidence.

Obesity, or more accurately, body mass index (BMI), would seem to be a risk factor associated with increased PONV, but statistical studies do not bear this out. Statistically, women on the 20th day of their menstrual cycle have the lowest incidence of PONV; the highest is on day five. Smoking, with its multitude of negative effects on the cardiovascular and respiratory system, would appear to be associated with higher incidence of PONV, but statistical studies indicate quite the opposite.

Droperidol (a butyrephenone, which is a dopaminergic antagonist), a very popular antiemetic, has come under a cloud because of the recent communication regarding increased QT intervals and dysrhythmias. Even though this was reported at doses over 2 mg, it is likely that use at the 0.625 mg level also will decrease. Droperidol is known to unmask major anxiety in patients before surgery and can cause extrapyramidal reactions, agitation and dysphoria. [See related article about droperidol on page 19.]

Transdermal scopolamine (1.5 mg) recently has become available for PONV, though it has been used for the last 20 years for motion sickness. Even though it is an inexpensive, long-lasting and effective method of PONV treatment, one-third of the patients will suffer from dry mouth and up to one-eighth from dizziness.

Propofol, with its action on the cerebral cortex as well as its interactions with dopaminergic and serotoninergic receptors, has become the popular antiemetic anesthetic drug. Using propofol-ketamine in room air for spontaneously breathing patients simulates the conditions for general anesthesia and has a very low emetic potential.

Ondansetron has been studied extensively as an agent used in PONV as an extension of its use in chemotherapy-induced nausea and vomiting (CINV). Its effectiveness in combating PONV is comparable to droperidol without the cardiovascular or psychological side effects. Its use is probably limited by cost factors more than anything else. It is probably the most used rescue medication for PONV and, in some places, the most used prophylactic antiemetic as well. Dolasetron, the other major 5HT3 antagonist, had garnered support with its financial argument over ondensetron since both have similar pharmacological profiles and similar side effects, namely headache, dizziness and diarrhea.

Dexamethasone in a single dose of 5 or 10 mg appears to have no toxic effects in otherwise healthy individuals while having a significant reduction in late PONV. Possibly the best results may be obtained by combining dexamethasone with a 5HT3 antagonist or droperidol.

Of all the neurotransmitters implicated in triggering emesis, the tachykinin substance P has been shown to play a key role in emetic responses because of its location in the brain's emetic regions as well as in the gastrointestinal vagal efferent. Substance P has been shown to induce vomiting when administered intravenously to laboratory animals. Substance P is postulated to be the endogenous ligand for neurokinin1 (NK1) receptors, and NK1 receptor antagonists have shown much promise as effective treatment in both CINV and PONV.

Nonpharmacological techniques used in management of PONV include acupuncture, acupressure, electroacupuncture, acupoint stimulation and transcutaneous electrical nerve stimulation. Use of acupuncture, acupressure and laser stimulation of pericard 6 located near the wrist has been shown to be effective prophylaxis of PONV. Interestingly, acupuncture offers no benefit to children, possibly indicating that if you do not expect relief, you will not find it. Acupuncture has been shown to be effective not only in the treatment of CINV and PONV but also in headache, low-back pain, alcoholism and even in paralysis secondary to stroke.

One gram of ginger preoperatively has been shown to be more effective than placebo in the treatment of PONV. Deep breathing, the first response asked of by PACU nurses, along with a cool washcloth on the forehead, may be more effective than we would like to believe. Deep inhalation of vapors of alcohol, peppermint or even saline seem to decrease nausea scores by 50 percent in less than five minutes.

Given all this, is the goal of zero PONV achievable? Is it desirable? Is it beneficial? Yes, yes and yes! Combining all the modalities available to us, from propofol to ondansetron, from total intravenous anesthesia to gentle reambulation, from not forcing the patient to partake of oral fluids prior to discharge from the PACU, to telling the transportation orderly to drive patient-friendly, would all go a long way in decreasing the incidence of PONV in our practice. Patients that pass through our hands in our care and suffer no nausea or vomiting will thank us from the bottom of their stomachs.


Bibliography:
Borgeat A, Stirnemann HR. Antiemetic effects of propofol [article in German]. Anaesthesist. 1998; 47(11):918-924.

Culy CR, et al. Ondansetron: A review of its use as an antiemetic in children. Paediatr Drugs. 2001; 3(6):441-479.

Diemunsch P, Grelot L. Potential of substance P antagonist as antiemetics. Drugs. 2000; 60(3):533-546.

Eberhart LH, et al. The menstruation cycle in the postoperative phase. Its effect of the incidence of nausea and vomiting [article in German]. Anaesthesist. 2000; 49(6):532-536.

Ernest E, Pittler MH. Efficacy of ginger for nausea and vomiting: A systematic review of randomized clinical trials. Br J Anaesth. 2000; 84(3):367-371.

Friedberg BL. Propofol-ketamine technique: Dissociative anesthesia for office surgery. Anesthetic Plast Surg. 1999; 23(1):70-75.

Henzi I, et al. Dexamethasone for the prevention of postoperative nausea and vomiting: A quantitative systemic review. Anesth Analg. 2000; 90(1):186-194.

Kovac AL. Prevention and treatment of postoperative nausea and vomiting. Drugs. 2000; 59(2):213-243.

Kranke P, Apefel CC, et al. An increased body mass index is no risk factor for postoperative nausea and vomiting. Acta Anaesthesiol Scand. 2001; 45(2):160-166.

Lee A, Done AL. The use of nonpharmacologic techniques to prevent postoperative nausea and vomiting: A metaanalysis. Anesth Analg. 1999; 88(6):1362-1369.

Mayer DJ. Acupuncture: An evidence-based review of the clinical literature. Annu Rev Med. 2000; 51:49-63.

Rodrigo C. The effect of cigarette smoking on anesthesia. Anesth Prog. 2000; 47(4):143-150.


  Ashish C. Sinha, M.D., Ph.D., is Assistant Professor of Anesthesiology, Department of Anesthesiology, University of Texas M.D. Anderson Cancer Center, Houston, Texas.

 


 



FEATURES

2001 ASA Annual Meeting: Our Foundations Are Strong

ARTICLES

DEPARTMENTS

The views expressed herein are those of the authors and do not necessarily represent or reflect the views, policies or actions of the American Society of Anesthesiologists.

NL Archives

Information for Authors